Hepatitis C is caused by infection with the Hepatitis C virus (HCV). Transmission is predominately through the blood-to blood route where persons such as current or former injection drug users, past recipients of blood transfusions or solid organ transplants and chronic hemodialysis patients are examples of risk groups. HCV infection becomes chronic in 75-85% of cases and if left untreated can result in chronic liver disease, cirrhosis and hepatocellular carcinoma (HCC). The WHO estimates that about 3% of the world's population has been infected with HCV and that some 170 million are chronic carriers at risk.This MarketVIEW product contains two comprehensive MS Excel-based models + summary presentation which forecast the potential commercial value of Hepatitis C Virus (HCV) TX and PX vaccines across major Western markets until 2030. The models contain value ($ m) and volume (mio doses) predictions per product type along with timeframe, pricing and penetration estimates for all adult risk groups. The product also includes an in depth review of latest HCV epidemiological trends, developments in new antivirals and immunological based treatments.THIS PRODUCT IS A EXECUTIVE PRESENTATION + 2 MODELS

1. ReportLinker
Find Industry reports, Company profiles
and Market Statistics
>> Get this Report Now by email!
MarketVIEW: Hepatitis C virus vaccines
Published on February 2013
Report Summary
Hepatitis C is caused by infection with the Hepatitis C virus (HCV). Transmission is predominately through the blood-to blood route
where persons such as current or former injection drug users, past recipients of blood transfusions or solid organ transplants and
chronic hemodialysis patients are examples of risk groups. HCV infection becomes chronic in 75-85% of cases and if left untreated
can result in chronic liver disease, cirrhosis and hepatocellular carcinoma (HCC). The WHO estimates that about 3% of the world's
population has been infected with HCV and that some 170 million are chronic carriers at risk.
This MarketVIEW product contains two comprehensive MS Excel-based models + summary presentation which forecast the potential
commercial value of Hepatitis C Virus (HCV) TX and PX vaccines across major Western markets until 2030. The models contain
value ($ m) and volume (mio doses) predictions per product type along with timeframe, pricing and penetration estimates for all adult
risk groups. The product also includes an in depth review of latest HCV epidemiological trends, developments in new antivirals and
immunological based treatments.
THIS PRODUCT IS A EXECUTIVE PRESENTATION + 2 MODELS
Table of Content
Author's note
Executive Summary
Commercial model: major outputs
HCV TX vaccines: revenues ($m) by scenario
HCV TX vaccines: revenues ($m) by region
HCV PX vaccines: revenues ($m) by scenario
HCV PX vaccines: revenues ($m) by region
Chronically infected HCV population (000s), by region, 2010-2030
Treated patients (000s), any antiviral therapy (all genotypes), by region, 2010-2030
Treated patients (000s), any antiviral therapy (genotype 1), by region, 2010-2030
Commercial model: key assumptions
The role of HCV TX vaccine
The role of HCV PX vaccine
Key inputs: TX vaccine
Key inputs: PX vaccine
Overview of modelling strategy: TX vaccine
Pricing: TX vaccine
Overview of modelling strategy: PX vaccine
Pricing: PX vaccine
Epidemiology inputs: HCV prevalence
Epidemiology inputs: HCV populations by genotype
Epidemiology inputs: Estimated HCV populations by genotype, 2010
MarketVIEW: Hepatitis C virus vaccines (From Slideshare)
Page 1/5

2. ReportLinker
Find Industry reports, Company profiles
and Market Statistics
>> Get this Report Now by email!
Epidemiology inputs: Injecting drug users
Epidemiology inputs: Estimated treatment rates (% of chronically infected HCV population)
HCV epidemiology summary
US: epidemiology
Europe: epidemiology
Canada: epidemiology
Japan, South Korea, Australia: epidemiology
HCV genotype distribution
Current HCV treatments ' review of latest clinical data
Future HCV therapies
HCV vaccine pipeline
Okairos (TerCvax and ProCvax)
Globeimmune (GI-5005)
ChronTech (ChronVac-C)
Transgene (TG4040)
Further methodology
Bibliography
About VacZine Analytics
Disclaimer
PAGES: ~75 MS PowerPoint slides, fully referenced/sourced. Available in .pdf form
Contents ' Vaccine demand model TX vaccine (MS Excel-based)
Title sheet
CHARTS ' VALUE
CHARTS ' VOLUME
CHARTS ' Epi
Value
Volume
Epi
Country worksheets '
US
Canada
Australia
France
Germany
Italy
Spain
UK
Other Europe
Japan
South Korea
Australia
Source material '
Total population
15-64 yrs population
TX vaccine price summary
MarketVIEW: Hepatitis C virus vaccines (From Slideshare)
Page 2/5

3. ReportLinker
Find Industry reports, Company profiles
and Market Statistics
>> Get this Report Now by email!
HCV prevalence
Genotype (% distribution)
Genotype prevalence (number)
IDUs
Treatment rates
HCV cases US
HCV cases UK
HCV cases Germany
HCV cases by risk group
Incivek sales
Clinical trials
Treatment pathway
Back page
Worksheets = 40 interconnected
Contents ' Vaccine demand model PX vaccine (MS Excel-based)
Title sheet
CHARTS ' VALUE
CHARTS ' VOLUME
Value
Volume
Epi
Country worksheets '
US
Canada
Australia
France
Germany
Italy
Spain
UK
Other Europe
Japan
South Korea
Australia
Source material '
Total population
15-64 yrs population
IDUs
Vaccine price summary
Back page
Worksheets = 40 interconnected
MarketVIEW: Hepatitis C virus vaccines (From Slideshare)
Page 3/5

4. Find Industry reports, Company profiles
and Market Statistics
ReportLinker
>> Get this Report Now by email!
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to:
Europe, Middle East and Africa : + 33 4 37 37 15 56
Asia, Oceania and America : + 1 (805) 617 17 93
If you have any questions please visit http://www.reportlinker.com/notify/contact
Order Information
Please verify that the product information is correct and select the format(s) you require.
MarketVIEW: Hepatitis C virus vaccines
Product Formats
Please select the product formats and the quantity you require.
1 User License--USD 9 995.00
Quantity: _____
Contact Information
Please enter all the information below in BLOCK CAPITALS
Title:
Mr
Mrs
Dr
Miss
Ms
Prof
First Name:
_____________________________ Last Name: __________________________________
Email Address:
__________________________________________________________________________
Job Title:
__________________________________________________________________________
Organization:
__________________________________________________________________________
Address:
__________________________________________________________________________
City:
__________________________________________________________________________
Postal / Zip Code:
__________________________________________________________________________
Country:
__________________________________________________________________________
Phone Number:
__________________________________________________________________________
Fax Number:
__________________________________________________________________________
MarketVIEW: Hepatitis C virus vaccines (From Slideshare)
Page 4/5

5. Find Industry reports, Company profiles
and Market Statistics
ReportLinker
>> Get this Report Now by email!
Payment Information
Please indicate the payment method, you would like to use by selecting the appropriate box.
Payment by credit card
Card Number: ______________________________________________
Expiry Date
__________ / _________
CVV Number _____________________
Card Type (ex: Visa, Amex…) _________________________________
Payment by wire transfer
Crédit Mutuel
RIB : 10278 07314 00020257701 89
BIC : CMCIFR2A
IBAN : FR76 1027 8073 1400 0202 5770 189
Payment by check
UBIQUICK SAS
16 rue Grenette – 69002 LYON, FRANCE
Customer signature:
Please note that by ordering from Reportlinker you are agreeing to our Terms and Conditions at
http://www.reportlinker.com/index/terms
Please fax this form to:
Europe, Middle East and Africa : + 33 4 37 37 15 56
Asia, Oceania and America : + 1 (805) 617 17 93
MarketVIEW: Hepatitis C virus vaccines (From Slideshare)
Page 5/5